Cargando…

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease

BACKGROUND: Inhibiting catechol‐O‐methyltransferase extends the plasma half‐life of levodopa, potentially allowing physicians to optimize the levodopa regimen in patients with Parkinson's disease (PD) experiencing motor fluctuations. OBJECTIVES: To evaluate the effects of once‐daily opicapone o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira, Joaquim J., Poewe, Werner, Rascol, Olivier, Stocchi, Fabrizio, Antonini, Angelo, Moreira, Joana, Guimarães, Bruno, Rocha, José‐Francisco, Soares‐da‐Silva, Patrício
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804871/
https://www.ncbi.nlm.nih.gov/pubmed/36054562
http://dx.doi.org/10.1002/mds.29193
_version_ 1784862212047765504
author Ferreira, Joaquim J.
Poewe, Werner
Rascol, Olivier
Stocchi, Fabrizio
Antonini, Angelo
Moreira, Joana
Guimarães, Bruno
Rocha, José‐Francisco
Soares‐da‐Silva, Patrício
author_facet Ferreira, Joaquim J.
Poewe, Werner
Rascol, Olivier
Stocchi, Fabrizio
Antonini, Angelo
Moreira, Joana
Guimarães, Bruno
Rocha, José‐Francisco
Soares‐da‐Silva, Patrício
author_sort Ferreira, Joaquim J.
collection PubMed
description BACKGROUND: Inhibiting catechol‐O‐methyltransferase extends the plasma half‐life of levodopa, potentially allowing physicians to optimize the levodopa regimen in patients with Parkinson's disease (PD) experiencing motor fluctuations. OBJECTIVES: To evaluate the effects of once‐daily opicapone on levodopa plasma pharmacokinetics and motor response when added to two different levodopa dosing regimens. METHODS: A total of 24 patients with PD and motor fluctuations were enrolled in an exploratory, open‐label, modified cross‐over trial. Participants first received levodopa/carbidopa 500/125 mg (five intakes) for 2 weeks and were then randomly assigned (1:1) to levodopa/carbidopa 400/100 mg given over either four or five daily intakes plus opicapone 50 mg for an additional 2 weeks. Levodopa 12‐hour pharmacokinetics was the primary outcome (ie, excluding the effect of last/evening levodopa/carbidopa intake), with motor complications evaluated as secondary outcomes. RESULTS: Over 12‐hour pharmacokinetics and compared with five‐intake levodopa/carbidopa 500/125 mg without opicapone, maximal levodopa concentrations were similar or nonsignificantly higher on both levodopa/carbidopa 400/100 mg regimens plus opicapone. Despite a 100 mg lower total levodopa/carbidopa daily dose, adding opicapone 50 mg at least doubled the levodopa plasma half‐life and minimal concentrations, with a significant ≈30% increase in total exposure. The levodopa fluctuation index was only significantly lower for the five intakes plus opicapone regimen (difference of −71.8%; P < 0.0001). Modifications to levodopa pharmacokinetics were associated with decreased off time and increased on time. CONCLUSIONS: Combining opicapone 50 mg with a 100 mg lower daily dose of levodopa provides higher levodopa bioavailability with avoidance of trough levels. Despite the lower levodopa dose, modifying the levodopa pharmacokinetic profile with opicapone was associated with decreased off time and increased on time. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
format Online
Article
Text
id pubmed-9804871
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-98048712023-01-06 Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease Ferreira, Joaquim J. Poewe, Werner Rascol, Olivier Stocchi, Fabrizio Antonini, Angelo Moreira, Joana Guimarães, Bruno Rocha, José‐Francisco Soares‐da‐Silva, Patrício Mov Disord Research Articles BACKGROUND: Inhibiting catechol‐O‐methyltransferase extends the plasma half‐life of levodopa, potentially allowing physicians to optimize the levodopa regimen in patients with Parkinson's disease (PD) experiencing motor fluctuations. OBJECTIVES: To evaluate the effects of once‐daily opicapone on levodopa plasma pharmacokinetics and motor response when added to two different levodopa dosing regimens. METHODS: A total of 24 patients with PD and motor fluctuations were enrolled in an exploratory, open‐label, modified cross‐over trial. Participants first received levodopa/carbidopa 500/125 mg (five intakes) for 2 weeks and were then randomly assigned (1:1) to levodopa/carbidopa 400/100 mg given over either four or five daily intakes plus opicapone 50 mg for an additional 2 weeks. Levodopa 12‐hour pharmacokinetics was the primary outcome (ie, excluding the effect of last/evening levodopa/carbidopa intake), with motor complications evaluated as secondary outcomes. RESULTS: Over 12‐hour pharmacokinetics and compared with five‐intake levodopa/carbidopa 500/125 mg without opicapone, maximal levodopa concentrations were similar or nonsignificantly higher on both levodopa/carbidopa 400/100 mg regimens plus opicapone. Despite a 100 mg lower total levodopa/carbidopa daily dose, adding opicapone 50 mg at least doubled the levodopa plasma half‐life and minimal concentrations, with a significant ≈30% increase in total exposure. The levodopa fluctuation index was only significantly lower for the five intakes plus opicapone regimen (difference of −71.8%; P < 0.0001). Modifications to levodopa pharmacokinetics were associated with decreased off time and increased on time. CONCLUSIONS: Combining opicapone 50 mg with a 100 mg lower daily dose of levodopa provides higher levodopa bioavailability with avoidance of trough levels. Despite the lower levodopa dose, modifying the levodopa pharmacokinetic profile with opicapone was associated with decreased off time and increased on time. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society John Wiley & Sons, Inc. 2022-08-31 2022-11 /pmc/articles/PMC9804871/ /pubmed/36054562 http://dx.doi.org/10.1002/mds.29193 Text en © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Ferreira, Joaquim J.
Poewe, Werner
Rascol, Olivier
Stocchi, Fabrizio
Antonini, Angelo
Moreira, Joana
Guimarães, Bruno
Rocha, José‐Francisco
Soares‐da‐Silva, Patrício
Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
title Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
title_full Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
title_fullStr Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
title_full_unstemmed Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
title_short Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
title_sort effect of opicapone on levodopa pharmacokinetics in patients with fluctuating parkinson's disease
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804871/
https://www.ncbi.nlm.nih.gov/pubmed/36054562
http://dx.doi.org/10.1002/mds.29193
work_keys_str_mv AT ferreirajoaquimj effectofopicaponeonlevodopapharmacokineticsinpatientswithfluctuatingparkinsonsdisease
AT poewewerner effectofopicaponeonlevodopapharmacokineticsinpatientswithfluctuatingparkinsonsdisease
AT rascololivier effectofopicaponeonlevodopapharmacokineticsinpatientswithfluctuatingparkinsonsdisease
AT stocchifabrizio effectofopicaponeonlevodopapharmacokineticsinpatientswithfluctuatingparkinsonsdisease
AT antoniniangelo effectofopicaponeonlevodopapharmacokineticsinpatientswithfluctuatingparkinsonsdisease
AT moreirajoana effectofopicaponeonlevodopapharmacokineticsinpatientswithfluctuatingparkinsonsdisease
AT guimaraesbruno effectofopicaponeonlevodopapharmacokineticsinpatientswithfluctuatingparkinsonsdisease
AT rochajosefrancisco effectofopicaponeonlevodopapharmacokineticsinpatientswithfluctuatingparkinsonsdisease
AT soaresdasilvapatricio effectofopicaponeonlevodopapharmacokineticsinpatientswithfluctuatingparkinsonsdisease